EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open access · CC BY-NC-ND 4.0

The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension

Karen Liao iD, Harald Mackenzie, Sihem Ait-Oudhia iD, Solaiappan Manimaran iD, Yiyuan Zeng, Tad Akers, Tatyana Yun, Janethe de Oliveira Pena iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3116 ↗

At a glance

Randomisierte kontrollierte Studie in Clinical Pharmacology & Therapeutics, 2024. Written by Karen Liao and 7 co-authors. Institution: Merck & Co., Inc., Rahway, New Jersey, USA. Major MEDLINE topics: Pulmonary Arterial Hypertension, Antineoplastic Agents. Cited 15 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Acceleron Pharma Inc..

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Sotatercept, a soluble fusion protein comprising the extracellular domain of activin receptor type IIA linked to the Fc portion of human IgG1, is a first‐in‐class activin signaling inhibitor under development for the treatment of pulmonary arterial hypertension (PAH). We evaluated antidrug antibody (ADA) development and determined the effects of immunogenicity on the pharmacokinetics (PKs), efficacy, and safety of sotatercept in STELLAR, a multicenter, double‐blind phase III trial (NCT04576988) wherein participants with PAH were randomized 1:1 to receive sotatercept (starting dose 0.3; target dose 0.7 mg/kg) or placebo subcutaneously every 3 weeks in combination with background therapies for ≤ 72 weeks. ADA‐positive (ADA‐POS) participants were identified and characterized for neutralizing antibodies (NAbs). PKs, efficacy, and safety were evaluated by ADA and NAb status. Of 162 evaluable participants, 42 (25.9%) were ADA‐POS through week 24, of whom 11 (6.8%) were also NAb‐POS. Median onset of ADAs was 3.29 weeks (interquartile range (IQR): 3.14–6.14), and median duration was 6 weeks (IQR: 3.14–17.86). No clinically meaningful differences were found across subgroups that were ADA‐NEG, ADA‐POS/NAb‐NEG, and ADA‐POS/NAb‐POS, in terms of PKs (sotatercept trough concentration over time, mean postdose trough concentration at the end of treatment, and clearance), efficacy (changes from baseline in 6‐minute walk distance, pulmonary vascular resistance, and N‐terminal pro‐B‐type natriuretic peptide levels), and safety (incidence of hypersensitivity, anaphylactic reactions, and administration site reactions). We conclude that ADA incidence from sotatercept treatment was 25.9% and did not meaningfully affect the PKs, efficacy, or safety of sotatercept in participants with PAH.

Subjects

MeSH terms (MEDLINE)

Pulmonary Arterial HypertensionAntineoplastic AgentsHumansRecombinant Fusion ProteinsAntibodies, NeutralizingTreatment Outcome

Substances

Antineoplastic AgentsRecombinant Fusion ProteinsAntibodies, Neutralizingsotatercept

Authors and institutions

  • Merck & Co., Inc., Rahway, New Jersey, USA.

ORCID profiles: Karen Liao, Sihem Ait-Oudhia, Solaiappan Manimaran, Janethe de Oliveira Pena

Funding

  • Acceleron Pharma Inc.

Cite

APA

Liao, K., Mackenzie, H., Ait-Oudhia, S., Manimaran, S., Zeng, Y., Akers, T., Yun, T., & de Oliveira Pena, J. (2024). The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3116

Vancouver

Liao K, Mackenzie H, Ait-Oudhia S, Manimaran S, Zeng Y, Akers T, et al. The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3116

BibTeX
@article{Liao2024,
  author = {Liao, Karen and Mackenzie, Harald and Ait-Oudhia, Sihem and Manimaran, Solaiappan and Zeng, Yiyuan and Akers, Tad and Yun, Tatyana and de Oliveira Pena, Janethe},
  title = {The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3116}
}
Start for free →